SUBSCRIBE: Print / eNewsletter
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to implement shared decision-making when discussing treatment options with your patients.
Robert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.
Overcoming resistance and determining better treatment plans that address the underlying disease biology of mantle cell lymphoma.
Mario Sznol, MD, from Yale University, discusses where the field of immune-oncology will be 1 and 5 years from now at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions.
In our lung cancer quiz, you'll get a chance to test your knowledge of the management of sarcopenia in patients with lung cancer.
Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Atezolizumab monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment in patients with wild-type non–small cell lung cancer with PD-L1 expression ≥50%.
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
